Richard A. Scolyer

1. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
   2017/10/13 by Jeffrey E. Gershenwald, Richard A. Scolyer, Kenneth R. Hess +13 · 37 citations
   Medicine · Biochemistry, Genetics and Molecular Biology · #Cutaneous Melanoma Detection and Management #Melanoma and MAPK Pathways #Cell Image Analysis Techniques
2. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
   2020/02/05 by Ruibin Xi, Dhawal Jain, Youngsook L. Jung +1341 · 10 citations
   Biochemistry, Genetics and Molecular Biology · #Cancer Genomics and Diagnostics #Genomic variations and chromosomal abnormalities #Genomics and Rare Diseases
3. Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
   2014/09/22 by Jinhua Wang, Sharon K. Huang, Diego M. Marzese +13 · 26 citations
   Biochemistry, Genetics and Molecular Biology · Medicine · #Melanoma and MAPK Pathways #Cutaneous Melanoma Detection and Management #Histone Deacetylase Inhibitors Research
4. Counting mitoses: SI(ze) matters!
   2021/06/02 by Ian A. Cree, Puay Hoon Tan, William D. Travis +5 · 3 citations
   Biochemistry, Genetics and Molecular Biology · Computer Science · Medicine · #AI in cancer detection #Cancer Genomics and Diagnostics #Radiomics and Machine Learning in Medical Imaging
5. The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway
   2020/02/14 by David E. Elder, Boris C. Bastian, Ian A. Cree +2 · 2 citations
   Biochemistry, Genetics and Molecular Biology · Medicine · #Cutaneous Melanoma Detection and Management #Melanoma and MAPK Pathways #Ocular Oncology and Treatments
6. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
   2021/04/20 by Christopher A. Muir, Christopher A Muir, Roderick J Clifton-Bligh +13 · 26 citations
   Medicine · #Cancer Immunotherapy and Biomarkers #Thyroid Cancer Diagnosis and Treatment #Multiple and Secondary Primary Cancers
7. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation
   2020/12/30 by Elizabeth C. Paver, Wendy A. Cooper, Andrew J. Colebatch +10 · 1 citation
   Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · Medicine · #Cancer Genomics and Diagnostics #Cancer Immunotherapy and Biomarkers #Immunotherapy and Immune Responses